Strategic Partnerships Leverage SystImmune's ongoing collaboration with Bristol Myers Squibb for iz a-bren to position co-development or co-commercialization opportunities in additional solid tumor indications and outside China where partnerships may unlock global access.

Late Stage signals Strong late-stage readouts and an asset portfolio spanning ADCs and bispecifics suggest demand for enabling technologies, manufacturing capacity, and strategic licensing deals to accelerate global trials and commercialization.

Clinical momentum Active participation in high-profile conferences (ASCO, ELCC) and multiple Phase 1/late-stage programs indicate a need for CRO/CMO services, regulatory affairs support, and data management partnerships to sustain momentum.

Global expansion Collaboration outside of China and ongoing asset sales indicate opportunities to offer international regulatory strategy, regional market access, and localized manufacturing services to support cross-border clinical and commercial activities.

Biologics focus Specialization in bispecifics, tri-specifics, and ADCs with tumor microenvironment targeting suggests sales opportunities for specialized procurement of biologics development tools, analytical services, and platform licensing to advance pipeline advancements.